Department of Surgical Sciences, CIR-Dental School, University of Turin, Turin, Italy.
Unit of Epidemiology, Regional Health Service ASL TO3, Grugliasco, Italy.
Oral Dis. 2018 Jul;24(5):772-777. doi: 10.1111/odi.12821. Epub 2018 Mar 13.
To perform a randomized, placebo-controlled, double-blind study, with a follow-up period of 6 months, for the use of topical clobetasol in cases of symptomatic oral lichen planus (OLP).
Thirty-two participants were analyzed, with the aims of: (I) to compare the usefulness of topically applied clobetasol propionate 0.05% (mixed with 4% hydroxyethyl cellulose gel) and 4% hydroxyethyl cellulose gel alone (considered as placebo) in the management of OLP; (II) to describe which of them is quicker in decreasing signs and reported symptoms, and (III) which is able to give the proper longer remission in the follow-up.
Symptoms improved in all clobetasol-treated patients during the first 2 months of therapy, while only 50% of placebo control group (p = .005) displayed similar results; of the remaining half, 12.5% did experienced a worsening while 37.5% remained stable. Regarding clinical signs, 87.5% of clobetasol-treated patients improved, while only 62.5% of the placebo-treated patients had a positive response (p = .229).
It is possible to report that clobetasol, at this dosage, has been more effective than a placebo at provoking symptoms improvement in subjects affected by atrophic-erosive oral lesions.
进行一项随机、安慰剂对照、双盲研究，随访期为 6 个月，评估局部应用氯倍他索治疗有症状的口腔扁平苔藓（OLP）的效果。
共分析了 32 名参与者，旨在：（I）比较局部应用氯倍他索丙酸酯 0.05%（与 4%羟乙基纤维素凝胶混合）和单独使用 4%羟乙基纤维素凝胶（作为安慰剂）在 OLP 治疗中的有效性；（II）描述它们中哪一种能更快地减轻症状和报告的症状；（III）在随访中哪一种能提供更长时间的适当缓解。
在治疗的前 2 个月，所有接受氯倍他索治疗的患者的症状都有所改善，而安慰剂对照组只有 50%（p=0.005）显示出类似的结果；其余一半中，12.5%的患者病情恶化，而 37.5%的患者病情稳定。关于临床体征，87.5%的接受氯倍他索治疗的患者得到改善，而只有 62.5%的接受安慰剂治疗的患者有积极反应（p=0.229）。
可以报告说，在这种剂量下，氯倍他索在引起萎缩性糜烂性口腔病变患者的症状改善方面比安慰剂更有效。
